1. Home
  2. DNLI vs OGN Comparison

DNLI vs OGN Comparison

Compare DNLI & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Denali Therapeutics Inc.

DNLI

Denali Therapeutics Inc.

HOLD

Current Price

$18.63

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Logo Organon & Co.

OGN

Organon & Co.

SELL

Current Price

$13.76

Market Cap

3.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
DNLI
OGN
Founded
2013
1923
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.6B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
DNLI
OGN
Price
$18.63
$13.76
Analyst Decision
Strong Buy
Hold
Analyst Count
20
5
Target Price
★ $35.75
$11.25
AVG Volume (30 Days)
1.8M
★ 1.9M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
N/A
★ 0.58%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.95
Revenue
N/A
★ $6,216,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$158.26
$2.51
P/E Ratio
★ N/A
$14.46
Revenue Growth
★ N/A
N/A
52 Week Low
$13.75
$5.69
52 Week High
$27.30
$13.83

Technical Indicators

Market Signals
Indicator
DNLI
OGN
Relative Strength Index (RSI) 41.65 53.95
Support Level $18.07 $13.46
Resistance Level $20.84 $13.77
Average True Range (ATR) 0.82 0.04
MACD 0.09 -0.00
Stochastic Oscillator 47.64 42.31

Price Performance

Historical Comparison
DNLI
OGN

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

About OGN Organon & Co.

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

Share on Social Networks: